Metastatic cancer, Epithelial tumours research hub

Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)

This study is looking into a new treatment called NG-641, used with an existing cancer medicine (nivolumab or similar), for people with advanced or spreading cancer. It's a very early-stage trial, focusing on safety and how the new treatment works in the body.